Eagle Pharmaceuticals (EGRX) announced the appointment of Christopher Krawtschuk as CFO of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Steven Ratoff stepped down from his role as interim CFO and will remain as a director on the Company’s board of directors. Most recently, Mr. Krawtschuk served as CFO and Treasurer of bluebird bio.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EGRX:
- Eagle Pharmaceuticals Implements Stockholder Rights Plan
- Eagle Pharmaceuticals adopts limited duration stockholder rights plan
- Eagle Pharmaceuticals Navigates Financial Uncertainty and Defaults
- Eagle Pharmaceuticals says in default under credit agreement
- Eagle Pharmaceuticals delays annual report on Form 10-K filing